Johns Hopkins University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
108
About the Report
About the Report
Summary
Johns Hopkins University (JHU) is a research university which offers undergraduate, graduate, master's, and doctoral programs. It offers educational services in the areas of arts and sciences, engineering, business, medicine, nursing, public health, and advanced international studies. It also conducts research and developments programs on applied physics, projects administration, natural sciences, engineering, technology, global research, and others. JHU offers undergraduate and postgraduate research services through its incubation center in the areas of drug development for cancer, mobile health platform, device to detect and prevent blindness caused by diabetes. The university operates through its campuses in the Baltimore-Washington region including Homewood, Harbor East, Peabody campus, SAIS Washington, SAIS Bologna and Montgomery County. JHU is headquartered in Baltimore, Maryland, the US.
Johns Hopkins University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Johns Hopkins University, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Johns Hopkins University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Johns Hopkins University, Medical Devices Deals, 2012 to YTD 2018 13
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
Johns Hopkins University, Pharmaceuticals & Healthcare, Deal Details 18
Partnerships 18
BGI Genomics Enters into Agreement with Johns Hopkins University 18
Deerfield Enters into Co-Development Agreement with John Hopkins University 19
Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 20
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 21
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 22
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 23
Institute of Organic Chemistry and Biochemistry Enters into Co-Development Agreement with Johns Hopkins Medicine 24
Bayer HealthCare Enters into Agreement with Johns Hopkins University 25
VLP Therapeutics Enters into Research Agreement with John's Hopkins University Bloomberg School of Public Health 26
MaxCyte Enters into Research Agreement with Johns Hopkins University 27
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 28
Saudi Aramco Forms Joint Venture Agreement With Johns Hopkins Medicine 29
MedImmune Enters Into Research Agreement With Johns Hopkins University 30
Imec Enters Into Co-Development Agreement With Johns Hopkins University 31
Atherotech Diagnostics Enters Into Research Agreement With Johns Hopkins Ciccarone Center 32
US Patent Innovations Enters Into Technology Transfer Agreement With George Washington University And Johns Hopkins University 33
Licensing Agreements 34
Dracen Pharma Enters into Licensing Agreement with Johns Hopkins University and Institute of Organic Chemistry 34
Canopy Biosciences Enters into Licensing Agreement with Washington University in St. Louis and Johns Hopkins University 35
Medicines Patent Pool Enters into Licensing Agreement with John Hopkins University 36
Pharos Biologicals Signs Licensing Agreement with University School of Medicine 37
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 38
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 39
Tavec Enters into Licensing Agreement with John Hopkins University 40
Tokai Pharma Enters into Licensing Agreement with Johns Hopkins University 41
Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 42
Allakos Expands its Licensing Agreement with Johns Hopkins University School of Medicine 43
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 44
Cerecor Enters Into Option For Licensing Agreement With Johns Hopkins University For DAAO Inhibitors 45
GrayBug Enters into Licensing Agreement with Johns Hopkins University 46
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 47
NexImmune Enters into Licensing Agreement with John Hopkins University 48
Good Start Genetics Expands Licensing Agreement with Johns Hopkins University 49
Blade Therapeutics Enters into Licensing Agreement with Johns Hopkins University School of Medicine 50
PapGene Enters into Licensing Agreement with Johns Hopkins University 51
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 52
Johns Hopkins University-Key Competitors 53
Johns Hopkins University-Key Employees 54
Johns Hopkins University-Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Joint Venture 57
Recent Developments 58
Government and Public Interest 58
Aug 08, 2018: Johns Hopkins Kimmel Cancer Center researchers using big data to predict immunotherapy responses 58
Aug 07, 2018: Researchers uncover potential new drug targets in the fight against HIV 59
Aug 02, 2018: Decibel Therapeutics Research on The Role of Molecular Diversity in Neurons Critical for Hearing Published in Cell 61
Jun 25, 2018: Activating Two Receptors Along Chemical Pathways May Provide Pain Relief at a Lower Opioid Dose 62
Jun 25, 2018: Lethal Prostate Cancer Treatment May Benefit from Combination Immunotherapy 64
May 14, 2018: New Computational Strategy Designed for More Personalized Cancer Treatment 65
Apr 19, 2018: Putting Proteins in Their Proper Place: Penn Study Identifies System that Guides Misplaced Disease Proteins Back to the Nucleus 66
Feb 05, 2018: New Research Suggests Your Immune System Can Protect Against MRSA Infections 67
Feb 01, 2018: Study Shows Evidence of Severe and Lingering Symptoms in Some after Treatment for Lyme Disease 69
Feb 01, 2018: Bacteria Play Critical Role In Driving Colon Cancers 71
Jan 31, 2018: Towards an early diagnosis of Parkinson's disease from the speech 73
Jan 11, 2018: Johns Hopkins is the First Center in the United States Approved for Living Donor HIV-Positive to HIV-Positive Kidney Transplants 74
Jan 04, 2018: Researchers create novel compound targeting melanoma cells 75
Dec 28, 2017: Study Shows Increased Risk of Uterine Fibroids in African-American Women With a Common Form of Hair Loss 76
Dec 14, 2017: Team of bioethicists calls for rigorous trials for experimental fetal therapy 77
Dec 01, 2017: Johns Hopkins Scientists Propose Efficiency 'Rules' for Enhancing Use of New Gene Editing Technology 78
Nov 06, 2017: Researchers Report First-Ever Protein Hydrogels Made in Living Cells 80
Oct 23, 2017: BrightFocus Foundation Awards Grants to Three Hopkins Scientists Studying Diseases of Mind and Sight 81
Oct 12, 2017: Johns Hopkins Scientists Develop Experimental Nano-Chemo Particle to Treat Bladder Cancer 82
Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 84
Sep 21, 2017: Grant funds chemotherapy-free breast cancer therapy research 86
Sep 20, 2017: Johns Hopkins Professors to Receive USD 13.4 Million for MS Research 87
Sep 19, 2017: CPRIT awards USD 34M to UTSW for cancer research recruitment 88
Sep 05, 2017: AHN, Johns Hopkins Research Points Potential Way to Effective Immunotherapy Use for Esophageal Cancer Patients 90
Jun 12, 2017: Study Calls For Use of Better Outcome Measures in Clinical Trials for Fragile X Syndrome and Other Neurodevelopmental Disorders 91
Jun 07, 2017: New Class of Double-Duty Magnetic Nanoparticles Engineered to Lower Cancer's Defenses While Firing up Immune System 93
May 30, 2017: Reservoirs of Latent HIV Can Grow Despite Effective Therapy, Study Shows 95
May 26, 2017: New cellular target may put the brakes on cancer's ability to spread 97
Mar 23, 2017: New Study Finds That Most Cancer Mutations are Due to Random DNA Copying 'Mistakes' 98
Product News 100
Dec 06, 2017: The Leukemia & Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly Blood Cancer 100
Mar 08, 2018: CDI Labs Collaborates on Discovery of New Biomarkers for Zika Infection 102
Mar 08, 2018: Johns Hopkins Study Reveals Artificial Intelligence (AI)-Driven Mobile App Sweetch Reduces Blood Sugar Levels in Early Stage Diabetes Patients 103
Other Significant Developments 104
Apr 26, 2018: Smartphone App Keeps an 'Eye' on Daily Tuberculosis Therapy 104
Feb 15, 2018: amfAR Renews Investment in Bioengineering Approaches to Curing HIV 106
Jan 22, 2018: New Johns Hopkins center aims to unlock genetic mysteries of breast cancer 107
Appendix 108
Methodology 108
About GlobalData 108
Contact Us 108
Disclaimer 108
List of Figure
List of Figures
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Johns Hopkins University, Medical Devices Deals, 2012 to YTD 2018 13
List of Table
List of Tables
Johns Hopkins University, Pharmaceuticals & Healthcare, Key Facts 2
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Johns Hopkins University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Johns Hopkins University, Deals By Therapy Area, 2012 to YTD 2018 11
Johns Hopkins University, Medical Devices Deals, 2012 to YTD 2018 13
Johns Hopkins University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
BGI Genomics Enters into Agreement with Johns Hopkins University 18
Deerfield Enters into Co-Development Agreement with John Hopkins University 19
Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 20
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 21
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 22
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 23
Institute of Organic Chemistry and Biochemistry Enters into Co-Development Agreement with Johns Hopkins Medicine 24
Bayer HealthCare Enters into Agreement with Johns Hopkins University 25
VLP Therapeutics Enters into Research Agreement with John's Hopkins University Bloomberg School of Public Health 26
MaxCyte Enters into Research Agreement with Johns Hopkins University 27
Compugen Enters into Research Agreement with Johns Hopkins University School of Medicine 28
Saudi Aramco Forms Joint Venture Agreement With Johns Hopkins Medicine 29
MedImmune Enters Into Research Agreement With Johns Hopkins University 30
Imec Enters Into Co-Development Agreement With Johns Hopkins University 31
Atherotech Diagnostics Enters Into Research Agreement With Johns Hopkins Ciccarone Center 32
US Patent Innovations Enters Into Technology Transfer Agreement With George Washington University And Johns Hopkins University 33
Dracen Pharma Enters into Licensing Agreement with Johns Hopkins University and Institute of Organic Chemistry 34
Canopy Biosciences Enters into Licensing Agreement with Washington University in St. Louis and Johns Hopkins University 35
Medicines Patent Pool Enters into Licensing Agreement with John Hopkins University 36
Pharos Biologicals Signs Licensing Agreement with University School of Medicine 37
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 38
Progenics Pharmaceuticals Enters into Licensing Agreement with Johns Hopkins University 39
Tavec Enters into Licensing Agreement with John Hopkins University 40
Tokai Pharma Enters into Licensing Agreement with Johns Hopkins University 41
Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 42
Allakos Expands its Licensing Agreement with Johns Hopkins University School of Medicine 43
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 44
Cerecor Enters Into Option For Licensing Agreement With Johns Hopkins University For DAAO Inhibitors 45
GrayBug Enters into Licensing Agreement with Johns Hopkins University 46
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 47
NexImmune Enters into Licensing Agreement with John Hopkins University 48
Good Start Genetics Expands Licensing Agreement with Johns Hopkins University 49
Blade Therapeutics Enters into Licensing Agreement with Johns Hopkins University School of Medicine 50
PapGene Enters into Licensing Agreement with Johns Hopkins University 51
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 52
Johns Hopkins University, Key Competitors 53
Johns Hopkins University, Key Employees 54
Johns Hopkins University, Subsidiaries 55
Johns Hopkins University, Joint Venture 57
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.